Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options for 405,800 shares to new employees as part of their employment inducements. These options, issued on July 20, 2022, have an exercise price of $1.94 per share, matching the stock's closing price on the grant date. They feature a 10-year term and vesting over four years. Geron is focused on developing imetelstat, a telomerase inhibitor, for hematologic malignancies, with two ongoing Phase 3 clinical trials: IMerge and IMpactMF.
Geron Corporation announces an expansion of its loan facility with Hercules Capital and Silicon Valley Bank, increasing access from $75 million to $125 million. This amendment allows for an additional $50 million in potential non-dilutive capital in 2023, crucial for the company as it anticipates top-line results from the Phase 3 IMerge trial in January 2023. Funding aims to support operations and potential commercialization of imetelstat until mid-2024.
Geron Corporation (Nasdaq: GERN) has granted a non-statutory stock option to purchase 70,000 shares of common stock to a new employee as an induction measure. This option was granted on June 15, 2022, with an exercise price of $1.30 per share, equal to the stock's closing price on that date. The option vests over four years, starting with 12.5% after six months, subject to continued employment. Geron, focused on developing a telomerase inhibitor for hematologic malignancies, is conducting two Phase 3 trials: IMerge and IMpactMF.
Geron Corporation (NASDAQ: GERN) has appointed Faye Feller, M.D., as Executive Vice President and Chief Medical Officer effective July 9, 2022. She succeeds Dr. Aleksandra Rizo, who will move to a consulting role after leading imetelstat's development. Dr. Feller has significant experience with imetelstat, having been involved in its development at Geron and previously at Janssen. The company anticipates top-line results from the IMerge Phase 3 trial in early January 2023, which could lead to a New Drug Application submission for imetelstat in lower risk myelodysplastic syndromes.
Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options for an aggregate of 327,400 shares to new hires, effective May 18, 2022. The options have an exercise price of $1.30 per share and a 10-year term, vesting over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4). Geron is engaged in developing imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge and IMpactMF, targeting hematologic malignancies.
Geron Corporation (NASDAQ: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that CEO John A. Scarlett will present at the H.C. Wainwright Global Investment Conference. The on-demand presentation starts on May 24, 2022, at 7 a.m. ET. A webcast will be accessible in the Investor Relations section of Geron's website, with an archive available for 30 days after the event. Geron is advancing its lead candidate, imetelstat, through two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.
Geron Corporation (Nasdaq: GERN) reported its Q1 2022 financial results, highlighting a net loss of $30.1 million, unchanged EPS at $0.09, and revenues of $123,000. The company has $178 million in cash and marketable securities and completed a public offering in April, raising approximately $70 million. The company anticipates sufficient resources to support operations through the end of 2023. Key milestones include the upcoming Phase 3 IMerge trial results and the initiation of the IMproveMF study, aiming to enhance treatment options for hematologic malignancies.
Geron Corporation (NASDAQ: GERN) will release its first quarter 2022 financial results on May 9, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET the same day to discuss the results and recent developments. Geron is focused on developing imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis. The press release and webcast details are accessible on their website.
Geron Corporation (NASDAQ: GERN) announced the grant of non-statutory stock options for 505,800 shares of common stock to newly hired employees as an inducement for employment. The options, granted on April 20, 2022, have an exercise price of $1.47, matching the stock's closing price on that date. They have a 10-year term and will vest over four years, beginning with a 12.5% vesting at six months. Geron is focused on developing imetelstat, a telomerase inhibitor, currently in two Phase 3 clinical trials for hematologic malignancies.
Geron Corporation (NASDAQ: GERN) announced that CEO John A. Scarlett will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:45 p.m. ET. The presentation can be accessed via a live webcast on Geron's Investor Relations website, with an archived replay available for 30 days afterward.
Geron is focused on the development of imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
